Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 4
Submit an article Journal homepage
4,101
Views
23
CrossRef citations to date
0
Altmetric
Short Report

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up

Susanne K. Kjaera Unit of Virus, Lifestyle & Genes, Danish Cancer Society Research Center, Copenhagen, Denmark;b Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
View further author information
,
Mari Nygårdc Unit of HPV-Related Epidemiological Research, Department of Research, Cancer Registry of Norway, Oslo, NorwayView further author information
,
Karin Sundströmd Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenView further author information
,
Christian Munka Unit of Virus, Lifestyle & Genes, Danish Cancer Society Research Center, Copenhagen, DenmarkView further author information
,
Sophie Bergerc Unit of HPV-Related Epidemiological Research, Department of Research, Cancer Registry of Norway, Oslo, NorwayView further author information
,
Mensur Dzabice Karolinska University Laboratory, Clinical Pathology, Stockholm, SwedenView further author information
,
Katrin Elisabeth Fridrichf Department of Pathology, Akershus University Hospital, Lørenskog, NorwayView further author information
,
Marianne Waldstrømg Department of Pathology Vejle Hospital, Lillebaelt Hospital, Beriderbakken, Denmark;h Institute of Regional Health Science, University of Southern Denmark, Odense, DenmarkView further author information
,
Sveinung Wergeland Sørbyei Department of Clinical Pathology, University Hospital of North Norway, Tromsø, NorwayView further author information
,
Oliver Bautistaj Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Thomas Groupj Merck & Co., Inc., Kenilworth, NJ, USAView further author information
&
Alain Luxembourgj Merck & Co., Inc., Kenilworth, NJ, USAView further author information
 show all
Pages 943-949 | Received 31 Jul 2020, Accepted 11 Oct 2020, Published online: 16 Dec 2020

References

  • Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–59.
  • Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044.
  • Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen O-E, Kjaer SK, Ferenczy A, Kurman RJ, Ronnett BM, Stoler MH, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019;154(1):110–17. doi:10.1016/j.ygyno.2019.03.253.
  • Luxembourg A, Kjaer SK, Nygard M, Ellison MC, Group T, Marshall JB, Radley D, Saah A. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. Contemp Clin Trials. 2017;52:54–61. doi:10.1016/j.cct.2016.10.006.
  • Luxembourg A, Bautista O, Moeller E, Ritter M, Chen J. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials. 2015;42:18–25. doi:10.1016/j.cct.2015.02.009.
  • Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials. 2015;12(1):84–90. doi:10.1177/1740774514552110.
  • Else EA, Swoyer R, Zhang Y, Taddeo FJ, Bryan JT, Lawson J, Van Hyfte I, Roberts CC. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol. 2011;49(5):1907–12. doi:10.1128/JCM.00236-10.
  • Roberts CC, Swoyer R, Bryan JT, Taddeo FJ. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. J Clin Microbiol. 2011;49:1899–906.
  • Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw K-L, Nygård J, Nygård M. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196(10):1447–54. doi:10.1086/522863.
  • Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, et al. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2016;2:61–69. doi:10.1016/j.pvr.2016.03.002.
  • Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, Ágústsson ÁI, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020;23:100401. doi:10.1016/j.eclinm.2020.100401.
  • World Health Organization (WHO). Guidelines to assure the quality, safety and efficacy of recombinant HPV virus-like particle vaccines. 2006 [Accessed 2020 Jun 30]. http://screening.iarc.fr/doc/WHO_vaccine_guidelines_2006.pdf.
  • Luxembourg A, Moeller E. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017;16:1119–39. doi:10.1080/14760584.2017.1383158.
  • Orumaa M, Leinonen MK, Campbell S, Møller B, Myklebust TÅ, Nygård M. Recent increase in incidence of cervical precancerous lesions in Norway: nationwide study from 1992 to 2016. Int J Cancer. 2019;145:2629–38. doi:10.1002/ijc.32195.
  • Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health. 2020;5(4):e213–e222. doi:10.1016/S2468-2667(20)30006-2.
  • Pedersen K, Burger EA, Nygard M, Kristiansen IS, Kim JJ. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018;91:68–75. doi:10.1016/j.ejca.2017.12.018.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.